

suggestive of fullerenes being stable relative to graphite. Also, much of the shungite consists of nominally amorphous carbon, which suggests that even on geological time scales, well-ordered material—be it graphite or fullerenes—does not necessarily form. Clearly, further work is required to understand the conditions needed to produce fullerenes in the geological environment.

Peter R. Buseck  
Semeon J. Tsipursky  
Departments of Geology and  
Chemistry/Biochemistry,  
Arizona State University, Tempe, AZ 85287

#### REFERENCES


1. D. Ugarte, *Nature* 359, 707 (1992).

#### Correction

In the final preparation of the manuscript of our report "Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains" (18 Sept., p. 1701) (1), we inadvertently plotted the data for figure 1C with an incorrect x axis: MgATP was plotted on the x axis instead of  $P_o$ . We did not immediately notice the error, which was brought to our

attention by Charles Venglarik and Robert Bridges, because the shape of the two curves is similar. The correct plot is shown in the figure below.

In both plots the data do not fit a straight



line, which supports our interpretation that more than one site may be involved with adenosine triphosphate (ATP) regulation of the cystic fibrosis transmembrane conductance regulator (CFTR). We regret any inconvenience this may have caused.

Michael J. Welsh  
Matthew P. Anderson  
Howard Hughes Medical Institute, and  
Departments of Internal Medicine and  
Physiology and Biophysics,  
University of Iowa College of Medicine,  
Iowa City, IA 52242

#### REFERENCES

1. M. P. Anderson and M. J. Welsh, *Science* 257, 1701 (1992).

#### Corrections and Clarifications

The table accompanying Larry Thompson's Research News article "At age 2, gene therapy enters a growth phase" (30 Oct., p. 744) incorrectly identified the principal investigators of gene therapy trials to treat kidney cancer and malignant melanoma being conducted at Memorial Sloan-Kettering Cancer Center and of a brain cancer experiment at the National Institutes of Health. The principal investigator of the Sloan-Kettering trials is Bernd Gansbacher, and the brain cancer study is being led by Edward Oldfield of the National Institute of Neurological Disorders and Stroke.

The News & Comment article "New French biomedical center breaks the mold" by Peter Aldous (25 Sept., p. 1856) neglected to mention the important financial contribution made by the Centre National de la Recherche Scientifique (CNRS) to the Cochin Institute for Molecular Genetics. CNRS provides almost half of the salaries of Cochin Institute personnel and supports one of its major research units.

The price listed for Franco Pavese and Gianfranco Molinar's *Modern Gas-Based Temperature and Pressure Measurements* (Plenum Press) in the Books Received column of 6 November (p. 1015) was incorrect. The price of the book is \$110.


When scientists at one of the world's largest research institutions were shopping for an off-the-shelf technical word-processing system, what program did they buy?

**SCIENTIFIC**  
The Difference is Intelligent Documents  
**word**

#### The one with...

- Full document editing of text AND mathematics
- Automatic equation numbering
- Windows interface to  $\text{T}_E\text{X}$  • ASCII  $\text{L}_A\text{T}_E\text{X}$  file format
- Customizable user interface and symbol bar
- Intelligent mathematics objects
- Typeset-quality output

At a Special Price of \$395 (Regularly \$595)



For brochure and information call:  
1-800-257-0073  
or  
(301) 459-3773  
FAX (301) 459-3776  
8201 Corporate Drive, Suite 1110  
Landover, MD 20785

**ARS Software**  
The Science and Technical Software Company

Scientific Word is a registered trademark of TCI Software Research, Inc.

Circle No. 21 on Readers' Service Card

## Cyclic GMP antagonist Rp-8-Br-cGMPS now available!

The R-isomer of 8-bromoguanosine - 3', 5' - cyclic monophosphorothioate (Rp-8-Br-cGMPS) blocks the signal transduction of the "second messenger" cyclic GMP by inhibition of cGMP - dependent protein kinase type I $\alpha$ . It is a novel and unique tool to prove a probable involvement of cyclic GMP in the biological system of interest. Developed and exclusively offered by BIOLOG, Cat. No.: B 005. Patent pending.

#### Outstanding properties:

- competitive inhibitor of cGMP - dependent protein kinase type I $\alpha$ , based on the widely accepted 8-Br-cGMP
- totally resistant against all known mammalian cyclic nucleotide - dependent phosphodiesterases
- good membrane permeability for many biosystems due to increased lipophilicity
- high stability and excellent solubility

Detailed technical information available.

**BIOLOG** - LIFE SCIENCE INSTITUTE -

Forschungslabor und Biochemia - Vertrieb GmbH

Head office:  
Schlachte 15/18,  
P.O. Box 10 71 25  
D-2800 Bremen 1, Germany  
Phone: 49 (0)421 133 92  
Fax: 49 (0)421 17 06 76

US/Canada distributor:  
Ruth Langhorst Int'l. Marketing  
7514 Girard Ave. Suite 1-411  
La Jolla, CA 92037  
Phone: (619) 457-1573  
Fax: (619) 456-0810

Circle No. 8 on Readers' Service Card